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The role of high-dose chemotherapy and peripheral blood progen-
itor cell rescue (HDCT) for responding metastatic or high-risk
primary breast cancer (HRBC) has been under evaluation for over
decade (Williams et al, 1989; Antman et al, 1992, 1997; Peters 
et al, 1993). Two small randomized studies could not confirm the
benefit of adjuvant HDCT (Hortobagyi et al, 1998; Rodenhuis 
et al, 1998). Preliminary data from a recently completed phase III
trial in patients with ³ 4 axillary nodes involved, suggest relapse-
free and overall survival benefit in the first 284 patients, however,
this benefit has not yet been confirmed in all 885 patients, there-
fore it is too soon to draw definite conclusions from this study
(Rodenhuis et al, 2000). Preliminary data from a phase III US trial
in HRBC suggested a decreased relapse rate, but at the cost of
unacceptably high treatment-related mortality following HDCT
with BCNU, cisplatin and cyclophosphamide (Peters et al, 1999).
In partially responsive stage IV breast cancer equivalent outcome
was observed with high-dose cyclophosphamide, thiotepa and
carboplatin (STAMP V) versus a median of 8 cycles of cyclophos-
phamide, methotrexate and 5-fluoruracil (CMF); no conclusion
regarding the potential benefit of HDCT in patients in complete
remission was reached in this study (Stadtmauer et al, 2000). 
Doxorubicin doses of 75–150 mg/m2 yield an 80% response rate
in stage IV breast cancer (Bronchud et al, 1989); low doses of
adjuvant doxorubicin (< 40 mg/m2/cycle) are associated with
diminished relapse-free survival, although no additional benefit
from moderately higher doses of doxorubicin (60 mg/m2 versus 
40 mg/m2) was observed (Wood et al, 1994). We previously tested
a doxorubicin-containing HDCT regimen (doxorubicin 165
mg/m2, etoposide 60 mg kg–1, and cyclophosphamide 100 mg kg–1
(CAVP) and observed an encouraging progression-free survival of
69% in patients with HRBC at 4.5 years; treatment-related
mortality was under 1% with mucositis as the most significant
toxicity; a projected ~20% progression-free survival in patients
with responsive stage IV disease was also seen (Somlo et al, 1993,
1997a; Doroshow et al, 1995). To replace the least effective agent,
etoposide, and to improve toxicity profile, we developed a novel
HDCT combination, inclusive of paclitaxel (Taxol®(T)), a drug
with reported response rates of 56% to 62% in patients with
metastatic breast cancer (Holmes et al, 1991; Reichman et al,
1993). Preclinical data favour prolonged adminstration of T;
increased dose/exposure enhances apoptosis (O’Shaughnessy 
et al, 1994; McCloskey et al, 1996). In the clinical setting, 24-hour
infusion of T results in higher response rates in stage IV breast
cancer than a 3-hour infusion (Mamounas et al, 1998). 
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Summary We assessed the feasibility and pharmacokinetics of high-dose infusional paclitaxel in combination with doxorubicin, cyclo-
phosphamide, and peripheral blood progenitor cell rescue. Between October 1995 and June 1998, 63 patients with high-risk primary [stage II
with ³ 10 axillary nodes involved, stage IIIA or stage IIIB inflammatory carcinoma (n = 53)] or with stage IV responsive breast cancer (n = 10)
received paclitaxel 150–775 mg/m2 infused over 24 hours, doxorubicin 165 mg/m2 as a continuous infusion over 96 hours, and
cyclophosphamide 100 mg kg–1. There were no treatment-related deaths. Dose-limiting toxicity was reversible, predominantly sensory
neuropathy following administration of paclitaxel at the 775 mg/m2 dose level. Paclitaxel pharmacokinetics were non-linear at higher dose
levels; higher paclitaxel dose level, AUC, and peak concentrations were associated with increased incidence of paraesthesias. No correlation
between stomatitis, haematopoietic toxicities, and paclitaxel dose or pharmacokinetics was found. Kaplan–Meier estimates of 30-month
event-free and overall survival for patients with primary breast carcinoma are 65% (95% CI; 51–83%) and 77% (95% CI; 64–93%). Paclitaxel
up to 725 mg/m2 infused over 24 hours in combination with with doxorubicin 165 mg/m2 and cyclophosphamide 100 mg kg–1 is tolerable. A
randomized study testing this regimen against high-dose carboplatin, thiotepa and cyclophosphamide (STAMP V) is currently ongoing. 
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doi: 10.1054/ bjoc.2001.1835, available online at http://www.idealibrary.com on  http://www.bjcancer.comHere, we report on the feasibility of combining 24-hour infu-
sional T with high-dose doxorubicin and cyclophosphamide
(ACT) and describe the pharmacokinetics of T and doxorubicin
and their effect on toxicity. Preliminary data on clinical outcome
are also reported. 
MATERIALS AND METHODS 
Eligibility 
This study was approved by the Institutional Review Board of the
City of Hope National Medical Center. All patients participating in
this trial gave written, voluntary informed consent. 
Patients with HRBC (stage II with ³ 4 axillary nodes involved,
stage IIIA, or stage IIIB carcinoma) or with responsive stage IV
disease (complete or partial response due to chemotherapy, radia-
tion treatment, or surgery, and confirmed twice at least 4 weeks
apart) were eligible. Patients were to start HDCT within 6 months
from completion of any standard chemotherapy and must not have
received any treatment for at least 4 weeks prior to enrolment on
this study. Prior exposure to doxorubicin of ≤ 180 mg/m2, and to
paclitaxel of ≤ 750 mg/m2, and for patients with metastatic disease
≤ 2 induction regimens were allowed. Patients who received prior
radiation to the left chest wall were excluded. A Karnofsky perfor-
mance status of ³ 80%, physiological age of ≤ 60 years, bilirubin
within normal range, ASAT and ALAT ≤ 2 x the upper limit of
normal, a measured creatinine clearance ³ 70 ml min–1, cardiac
left ventricular ejection fraction (LVEF) ³ 55% as documented by
cardiac radionuclide-gated pool scanning (MUGA), a forced expi-
ratory volume in 1 second (FEV1) of ³ 2 l, and diffusion capacity
> 60% of predicted, were required. Computed tomography (or
MRI) of the brain, chest, and abdomen, a bone scan, baseline
audiograms and nerve conduction studies and bilateral bone
marrow biopsies were required. A faculty pathologist reviewed
haematoxylin and eosin-stained slides of the primary tumour,
samples of metastases and bone marrow biopsies. Patients with
bone marrow or CNS metastases were excluded. 
Treatment plan 
Stem-cell (PBPC) procurement 
The majority of patients (n = 54) underwent mobilization with 
G-CSF (Filgrastim, Amgen Inc, Thousand Oaks, CA) 5 mg kg–1
bid, subcutaneously (sc); on the 5th day of priming apheresis
commenced and continued through collection of at least 8 ´ 108
mononuclear cells kg–1. Nine patients were enrolled on a phase II
randomized, placebo-controlled study of recombinant human
thrombopoietin (rhTPO), (Genentech Inc, South San Francisco,
CA) and/or G-CSF priming and post-reinfusion randomization
between placebo, rhTPO and G-CSF or GM-CSF (Immunex,
Seattle, WA); for these patients a minimum of 2 ´ 106 CD34+ cells
kg–1 and a target of > 5 ´ 106 CD34+ cells kg–1 were required.
PBPC were collected and were immediately cryopreserved as
reported earlier (Somlo et al, 1997a), except for 1 patient who
underwent CD34+ selection using an Isolex Magnetic Cell
Separator (Nexell Therapeutics Inc, Irvine, CA). 
High-dose chemotherapy regimen 
The HDCT schema and T dose escalation are illustrated in 
Figure 1. Ideal body weight was used when calculating doses.
Doxorubicin 165 mg/m2 was administered over 96 hours, between
days –9 and –5, followed by cyclophosphamide 100 mg kg–1 on
day –5, as reported earlier (Somlo et al, 1997b); a 24 hour contin-
uous i.v. infusion of T was started on day –4. 25% of PBPC were
reinfused on day –2 and 75% on 0 (Somlo et al, 1997b), except for
the 9 patients receiving rhTPO mobilization and 1 patient whose
PBPC were selected using the Isolex device; these patients
received their PBPC on day 0 and then were given a combination
of rhTPO and G-CSF or GM-CSF, or G-CSF alone. Supportive
care was provided as per institutional standards; G-CSF 5 mg kg–1,
bid, i.v. was started with the first stem cell reinfusion and
was continued through absolute granulocyte recovery (AGC) of 
³ 1 ´ 109 l–1 for 3 consecutive days (Somlo et al, 1997a). 
Toxicity grading and dose adjustments 
The dose of T was escalated as illustrated in Figure 1. Doxorubicin
and cyclophosphamide were administered without any dose modi-
fication. We utilized the NCI Division of Cancer Treatment
Common Toxicity Criteria for all organ toxicities except for the
hematologic and gastrointestinal systems, where we followed
guidelines we have incorporated in our prior HDCT trials (Somlo
et al, 1994, 1997a). The maximum tolerated dose of this regimen
(MTD) was defined as grade 3 toxicity for any system in 2 of 6
patients treated at that dose level after 21 days of observation. The
MTD was also to be established at any given dose level if a single
patient experienced grade 4 toxicity. Then, we planned to expand
the study to incorporate a total of 20 patients for treatment at
MTD-1 in order to gain more clinical experience and assess to
patient-to-patient variations of T pharmacokinetics. 
Pharmacokinetics 
Blood samples were drawn from a peripheral line immediately
prior to the start of the doxorubicin infusion, 48, 72 and 96 hours
during infusion, and at 2, 6, 12, 24 and 48 hours after completion
of the infusion. Plasma doxorubicin and doxorubicinol concentra-
tions were determined using a previously described loop-column
method (Riley et al, 1985). 
Peripheral blood samples were also obtained immediately prior
to the start of the T infusion, at 3, 6, 12, 20 and 24 hours during the
T infusion, then at 15 minutes, 30 minutes, 1, 2, 3, 6, 12 and 24
hours after completion of the infusion. The concentration of T in
plasma was measured according to a previously published HPLC
method (Rizzo et al, 1990). Pharmacokinetic data analyses of indi-
vidual plasma drug concentration versus time curves were
performed using ADAPT II software (Biomedical Simulations
Resource, University of Southern California, Los Angeles, CA).
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Cyclophosphamide
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iv over 2 hours
iv over 24 hours
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2
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X mg/m2
X = 150, 200, 275, 325, 375, 425, 525, 575, 625, 725, 775
Figure 1 High-dose chemotherapy schema and paclitaxel dose escalation Doxorubicin and doxorubicinol concentrations were fit simultane-
ously using a dual 2-compartmental pharmacokinetic model, while
T concentrations were fit with a previously described pharmacoki-
netic model incorporating both saturable distribution and saturable
elimination (Sonnichsen et al, 1994; Gianni et al, 1995). Adequacy
of the model derived fits were assessed by examination of resid-
uals between predicted and measured T concentrations, along with
the correlation coefficients. Doxorubicin, doxorubicinol and 
T AUCs were estimated using linear trapezoids, with the terminal
area extrapolated to infinity, using both the measured and fitted
drug concentrations. Doxorubicin and T systemic clearances
(CLsys) were determined using the relationship: CLsys = dose/AUC.
Peak plasma T concentrations were defined as the actual T levels
measured just prior to the end of the infusion. 
Post-HDCT management 
Radiation therapy 
Radiation therapy to the chest wall and draining lymph nodes at a
dose of 40–50 Gy (with boosts of 10–15 Gy to the primary site)
was offered to patients with stage II and IIIA/B breast cancer.
Patients treated for stage IV disease were to receive local-regional
radiation to control metastatic sites, as it was deemed feasible by
the treating physicians. 
Hormone therapy 
Following HDCT, tamoxifen 10 mg bid was prescribed to patients
with receptor positive high-risk breast cancer, or to those with
metastatic disease who had previously not failed tamoxifen. 
Response evaluation and post-treatment follow-up 
Patients were evaluated at day 30 and subsequently, at least once
every 4 months. Yearly mammograms and scans of previously
involved areas for patients with metastatic disease, were
performed at the time of follow-up, or as clinically indicated. A
MUGA scan and audiogram and nerve conduction studies were
repeated 30 days following HDCT. Standard response and progres-
sion criteria were applied (Somlo et al, 1994, 1997). 
Statistical analysis 
Outcomes examined included overall survival (OS) and relapse-
free survival (RFS), calculated from the first day of HDCT for
HRBC patients. OS and progression-free survival (PFS) in patients
with stage IV disease were calculated from the first day of HDCT.
The product-limit method of Kaplan–Meier was used when calcu-
lating projected survivals (Kaplan and Meier, 1958). Data entry
was censored as of 3/3/2000. Other data are summarized as median
and range, or as frequencies and percentages, as appropriate.
Association of T AUCs, peak concentrations and clearance with
toxicities, and in the 20 patients treated at the MTD-1 level (T 725
mg/m2) with body weight, ALAT, ASAT, alkaline phosphatase,
bilirubin, and age were evaluated by linear regression, Wilcoxon
rank-sum tests, and logistic regression. Significance levels are
reported as ‘P values’ and ‘significant’ denotes P < 0.05 when not
otherwise specified. Initial data management was done using SAS,
and statistical computing was done using SPlus 4.5 release 2. 
RESULTS 
Patients 
Between October 1995 and June 1998, 63 patients were entered on
study. Table 1 lists patient characteristics. The median age was 46
years (range, 29–61). All patients with primary breast cancer
received a doxorubicin-containing adjuvant regimen but only 1
patient received T prior to HDCT. The median length of time
between diagnosis and initiating HDCT was 4.9 months (range,
3.6–10.2). 
10 patients received HDCT for stage IV disease; all patients
received induction chemotherapy (doxorubicin-containing
regimen: 40%; doxorubicin and T: 40%; T-containing regimen:
20%). Of 5 patients in complete remission (CR) prior to HDCT, 3
patients underwent surgical removal of their local-regional metas-
tasis (lymph node, skin and chest wall lesions, respectively) first,
and proceeded to undergo ‘induction’ chemotherapy; 2 patients
achieved complete remission (CR) with induction therapy alone. 
Pharmacokinetic analysis 
Doxorubicin pharmacokinetics were examined in a subset of 6
patients; doxorubicin and doxorubicinol plasma concentrations rose
during the entire infusion, reaching a maximum of 50–70 ng ml–1
(0.1 mM). After the end of infusion, plasma doxorubicin concen-
trations declined in a bi-exponential manner. The mean doxoru-
bicin clearance was 28.6 ± 2.4 l /h/m2 and the mean doxorubicin to
doxorubicinol AUC ratio was 0.64 ± 0.2 (data not shown).
Comparison of the doxorubicin pharmacokinetic data with previ-
ously published findings demonstrate that doxorubicin clearance is
linear up to the doses used in the current study (Synold and
Doroshow, 1996). 
Paclitaxel (T) pharmacokinetic data are available from 52
patients at doses ranging from 150 to 775 mg/m2, including 16
patients treated at the MTD-1 of 725 mg/m2. Over the entire dose
range, T plasma concentration-versus-time data were best
described by a pharmacokinetic model incorporating saturable
distribution and clearance. Plasma AUC values ranged from 4.3 to
96.1 mM3h, and Cmax levels ranged from 2.1 to 52.1 mM. Figure 2
depicts the relationship between T dose and systemic clearance.
T clearances ranged from 52.1 to 8.8 1/h/m2, and
decreased with dose. As a result, both T AUC and Cmax increased
non-linearly with dose. Figure 3 demonstrates the non-linearity of
T AUC versus dose, with the relationship being best described by
a quadratic equation (P = 0.001). A non-linear increase in T Cmax
with increasing dose (P = 0.02) was also seen (not shown). 
In addition to the disproportionate increases in T AUC and Cmax
with increasing dose, variability in the measured systemic expo-
sure also increased over the entire dosing range (P < 0.00001 for
AUC and P = 0.0002 for Cmax). Within the group of patients treated
at the 725 mg/m2 dose level, T clearances ranged from 8.8 to
32.4 l /h/m2. As a result, T AUC in this cohort varied from 26.2 to
96.1 mM3h. The spread between the lowest and highest AUC and
peak concentrations in these patients was 3.7 fold and 2.5 fold,
respectively. Similarly wide ranges in AUC (Figure 3) and Cmax
(data not shown) were seen in patients treated with 625 mg/m2, 3.2
and 4.6 fold respectively. 
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tionship could be identified between T pharmacokinetics and any
of the laboratory parameters (ASAT, ALAT, bilirubin, alkaline
phosphatase) tested; likewise, no correlation existed between T
pharmacokinetics and either age or race (data not shown). We did
observe however, that patients who weighed < 120% of their ideal
body weight had significantly higher AUCs (82.2 mM3h (range,
59.9–96.1) vs. 54.8 mM3h (range, 26.2–91.5), P = 0.04), higher
Cmax (4.2 mM (range, 3.26–5.18) vs. 2.88 mM (range, 2.1–3.89), 
P = 003), and lower clearances (10.3 l/h/m2 (range, 8.83–14.2) vs.
15.5 l/h/m2 (range, 9.27–32.4), P = 0.04) than those patients
weighing > 120% of their ideal body weight. T AUC (P = 0.005),
Cmax (P = 0.01) and clearance (P = 0.005) were better correlated
with actual body weight than ideal body weight. However, in the
case of AUC, when one very large patient was omitted from the
analysis, the correlation became non-significant. 
Toxicity 
Neurotoxicity 
Neurotoxicity was dose-limiting. The incidence of paraesthesias,
nerve conduction abnormalities and grade 3 and 4 neurotoxicities
is illustrated in Table 2. The incidence of paraesthesias vs. AUC is
represented in Figure 3: while none of the patients treated at the
first 2 dose levels, and less than 30% of patients treated at the first
8 dose levels of T reported paraesthesias of the hands and feet,
reversible paraesthesias were reported by the majority of patients
treated with T ³ 575 mg/m2. T dose levels were highly predictive
for development of paresthesias (P = 0.0002); greater T AUC
(Figure 3) and peak concentrations (not shown) were also predic-
tive for the development of paraesthesias but not more than T dose
level (i.e. the amount of T/m2 delivered; P = 0.001 and P = 0.0002
by Wilcoxon rank sum test, data not shown). Although nerve
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Table 1 Patient characteristics 
N (%) Median (Range) 
Age at diagnosis, years 46 (29–61) 
Patients with stage II/IIIA/IIIB BC 53 (100) 
Patients with stage II BC 27 (51) 
IIIA/B BC 26 (49) 
ER and/or PR positive primary 38 (72) 
Treated with modified radical mastectomy 44 (83) 
Breast conservation 9 (17) 
Prior doxorubicin exposure 53 (100) 
Prior T exposure 1 (2) 
Prior radiation therapy 1 (2) 
Prior tamoxifen therapy 2 (4) 
Time from diagnosis to HDCT, months 4.9 (3.6–10.2) 
Radiation therapy post-HDCT 49 (93) 
Tamoxifen post HDCT 40 (76) 
No. of patients with stage IV BC 10 100 
ER and/or PR positive primary 9 (90) 
Prior adjuvant A-based regimen 2 (20) 
non-A containing regimen 5 (50) 
Induction with an A-based regimen± 4 (40) 
Induction with a combination of A and T 4 (40) 
Induction with T or T and Cytoxan 2 (20) 
No. of prior regimens for metastatic disease 1 (1–2) 
No. of induction chemotherapy cycles 3 (2–4) 
Time from diagnosis to onset of metastasis, months 30 (0–117) 
Time from onset of metastasis to HDCT, months 4.9 (3.8–24) 
Prior radiation therapy to primary site 1 (10) 
metastatic site 1 (10) 
Radiation therapy post HDCT 6 (60) 
Prior tamoxifen therapy as adjuvant 4 (40) 
Hormonal therapy post-HDCT 6 (60) 
Sites of metastasis by patient Response prior to HDCT Response post HDCT 
Chest wall CR (surgical) cCR* 
Lung PR CR 
Lymph node CR (surgical) cCR 
Bone PR cPR** 
Lymph node CR cCR 
Skin CR cCR 
Bone PR (radiated) cPR 
Lung/bone PR/stable cPR/SD 
Skin/bone CR/PR cCR/cPR 
Skin CR (surgical) cCR 
*Continuous CR; **continuous PR ±one patient received CMF followed by CAF. conduction studies were not available in all patients, more than
half of those patients who had undergone such studies and were
treated with T ³ 625 mg/m2 were found to have minimal to mild
peripheral sensory and/or motor neuropathies. We have found no
correlation between dose, peak concentration, or AUC and the
presence of nerve conduction abnormalities. There was however, a
trend correlating peak T concentration and dose-limiting grade 3/4
neurotoxicities (P = 0.06); grade 3/4 peripheral neuropathies were
associated with the highest dose levels of T (P = 0.04, data not
shown). The first grade 3 sensory neuropathy (difficulty with
handwriting) was observed in a patient treated at T 625 mg/m2. At
T 675 mg/m2 one patient developed grade 3 peripheral, primarily
sensory, neuropathy manifesting as minimal gait and balance diffi-
culties, with resolution of her symptoms in 5 months; a patient
with pre-existing Charcot–Marie–Tooth disease also developed
grade 3 sensory neuropathy manifesting as worsened handwriting;
her symptoms resolved in 3 months. Due to her pre-existing neuro-
logical condition, we accured a seventh patient at the same dose
level, who experienced no dose-limiting toxicities, hence T escala-
tion continued. During T dose escalation 1 of 6 patients treated
with T 725 mg/m2 developed reversible, primarily sensory periph-
eral neuropathies. One patient treated with T 775 mg/m2 devel-
oped a positive Romberg sign associated with grade 4 peripheral,
primarily sensory neuropathy, hence defining the MTD; her
symptoms slowly resolved in 8 months. The cohort of patients
treated with T 725 mg/m2 (MTD-1) was then expended to 20; 3 of
these patients experienced grade 3 sensory/motor neuropathies. 
Other toxicities 
There were no treatment-related deaths. Reversible grade 1/2
myalgias were observed in 1 patient each treated with T 150, 425,
475 and 525 mg/m2 and in 4 patients treated at 725 mg/m2. The
severity and grade of mucositis, measured as the median number
of days requiring narcotic analgesics (illustrated in Table 2) was
independent of the dose, AUC or peak concentrations of T. The
median number of days requiring hospitalization primarily due to
mucositis and neutropenic fever was 15.5 (range, 8–25) (data not
shown). There was no substantial decrease in LVEF as measured
by MUGA scan following HDCT (see Table 2). However, one
patient with prior radiation to the chest wall, and with subsequent
excision of a subcutaneous metastasis above the sternum had a
normal post-HDCT ejection fraction, but developed congestive
heart failure and a LVEF of 25% after receiving additional radia-
tion to the sternum. Her LVEF recovered to 45% with medical
management and she is currently without symptoms.
Haematopoietic toxicities were independent of T dose, AUC or
peak concentrations. The median number of days to reach an
absolute granulocyte count (AGC) of ³ 0.5 ´ 109l–1 and to reach
platelet transfusion independence were 9 and 8, respectively
(Table 2). One patient who had undergone mobilization with
rhTPO and G-CSF developed acute lymphocytic leukaemia with
4/11 translocation (11q23) 12 months after HDCT. She achieved
complete remission and is currently (18 months post induction) on
maintenance therapy. 
Treatment response 
With a median follow-up of 29 months (range 19–53 months) 30-
month projected overall survival is 77% (95% CI, 64–93%) and
relapse-free survival is 65% (95% CI, 51–83%) for patients with
stage II and III breast cancer (see Figure 4). Of 10 patients treated
for stage IV breast cancer 5 were in CR and 5 were in partial
response, one of whom achieved a CR following HDCT. 4 of 10
patients treated for stage IV disease relapsed. 
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 DISCUSSION 
The benefit of standard dose T as a 3-hour i.v. infusion subsequent
to adjuvant doxorubicin and cyclophosphamide in patients with
HRBC is unclear. The shorter infusion time may be responsible for
lack of clear benefit in HRBC (Henderson et al, 1998), and results
with such schedule are inferior in the metastatic setting
(Mamounas et al, 1998). High-dose 24-hour infusion of T was first
tested as a component of HDCT in stage IV disease. Escalating
doses of T with cyclophosphamide and cisplatin resulted in a 54%
overall response rate; severe sensory neuropathy and central
nervous system toxicity beyond T 775 mg/m2 were limiting
(Stemmer et al, 1996). Severe peripheral neuropathy was observed
with > T 775 mg/m2 (Vahdat et al, 1998) when T was administered
over 24-hours as part of a triple HDCT regimen, followed first by
melphalan and subsequent cyclophosphamide, thiotepa and carbo-
platin (STAMP V); this combination yielded a 74% overall
response rate. However, neurotoxicity was not reported when T
250 mg/m2 was infused over 3 hours as part of HDCT with carbo-
platin and cyclophosphamide, but, 2 of 21 HRBC patients died on
day 10, following reinfusion of CD34+ selected PBPC (Greinix 
et al, 2000). 
Since the majority of patients on our trial of ACT were treated
for HRBC, for the sake of safety we chose to escalate the dose of T
very carefully. We observed a diminished degree of mucositis and
haematopoietic toxicity compared to our experience with CAVP.
No patient treated with T 725 mg/m2 (the proposed phase II dose)
experienced grade 3 mucositis, versus 26% of patients treated with
our prior CAVP regimen (data not shown). Patients treated at the
MTD-1 dose of T 725 mg/m2 required hospitalization for mucosi-
ties and neutropenic fever for a median of 15.5 days (range, 8–25)
versus 29 days for patients treated with CAVP (data not shown).
Granulocyte recovery was similar following ACT versus CAVP at
this dose level, but platelet independence was achieved earlier
with ACT (data not shown). As for cardiac tolerance: a recent
phase I trial of a cyclophosphamide, mitoxantrone and 3–6 hour
infusion of T was associated with severe cardiac toxicities above T
400 mg/m2; a 24-hour schedule seems preferable (Gluck et al,
1998). 
T pharmacokinetics were predictive of haematopoietic toxici-
ties, mucositis and neurotoxicities at conventional dose levels
(Brown et al, 1991; Wilson et al, 1994; Gianni et al, 1997); we
observed such correlations only between dose, peak concentration,
AUC and development of paraesthesias. The dose-limiting toxicity
at T 775 mg/m2 was reversible peripheral neuropathy. Peak
concentrations and AUC of T were no more predictable for neuro-
toxicities then knowing the prescribed dose of T; the relatively
small sample size and wide interpatient pharmacokinetic vari-
ability might explain such phenomena. 
The observed relapse-free survival in patients with HRBC is in
keeping with our previous cohort of CAVP-treated patients at this
length of follow-up. The cohort of patients treated for stage IV
disease is too small to assess the value of this regimen in that
setting. 
In conclusion, high-dose chemotherapy with doxorubicin,
cyclophosphamide and infusional T (ACT) is feasible, but mucositis
necessitating the use of narcotic analgesics, reversible peripheral
neuropathy, and the requirement for hospitalization represent signif-
icant toxicities. T pharmacokinetics become non-linear at higher
dose levels with increasing interpatient variability, suggesting
saturable tissue distribution and/or elimination. Higher doses of T
are associated with an increased incidence of reversible peripheral
neuropathy. The potential therapeutic benefit and manageable toxi-
city profile of ACT needs to be further evaluated. Preliminary data
from a completed, randomized US, trial did not reveal a survival
benefit in patients with primary breast cancer, possibly due to unac-
ceptably high regimen-related mortality (Peters et al, 1999); no data
are available from another completed, randomized US trial, while
encouraging data from the Rodenhuis trial should be considered
preliminary (Rodenhuis et al, 2000). In the metastatic setting equiv-
alence of the STAMP V regimen to prolonged administration of
CMF was noted in patients in partial remission (Stadtmauer et al,
2000), while a smaller trial suggested improved relapse-free but
equivalent overall survival following HDCT versus conventional
treatment (Lotz et al, 1999). We are currently in the process of
comparing the toxicity and efficacy of ACT against the STAMP V
regimen in women with high-risk primary breast cancer. Should the
final results of completed randomized studies confirm the beneficial
role of HDCT in the treatment of selected patients, the less toxic,
and at least equally effective regimen can later be tested in a larger
phase III randomized trial. 
ACKNOWLEDGEMENTS 
We thank Judy Brent, Melissa Scalia and Tricia Taylor for their
assistance with the clinical aspects and data management and
preparation of this manuscript. This study was supported by grants
CA33572 and CA62505 from the National Cancer Institute Cancer
Center and by Bristol-Myers Squibb Corporation. 
REFERENCES 
Antman KH, Rowlins PA, Vaughan WP, Pelz CJ, Fay J, Fields K, Freytes C, Gale RP,
Hillner B, Holland K, Kennedy J, Klein J, Lazarus H, McCarthy P, 
Saez R, Spitzer G, Stadtmauer E, Williams S, Wolff S, Sobocinski K, Armitage J
and Horowitz M (1997) High-dose chemotherapy with autologous
hematopoietic support for breast cancer in North America. J Clin Oncol 15:
1870–1879 
Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L and Dexter TM (1989)
The use of granulocyte colony-stimulating factor to increase the intensity of
treatment with doxorubicin in patients with advanced breast and ovarian cancer.
Brit J Cancer 60: 121–125 
Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J,
and Von Hoff D (1991) A phase I trial of Taxol given by 6-hour intravenous
infusion. J Clin Oncol 9: 1261–1267 
Doroshow JH, Somlo G, Ahn C, Baker P, Rincon A, Forman S, Akman S, Chow W,
Coluzzi P, Hamasaki V, Leong L, Margolin K, Molina A, Morgan R, Rashko J,
Shibata S, tetef M, Yen Y and Brent J (1995) Prognostic factors predicting
progression-free (PFS) and overall survival (OS) in patients (PTS) with
responsive metastatic breast cancer (MBC) treated with high-dose
chemotherapy (HDCT) and bone marrow stem cell reinfusion. Proceedings of
Asco Vol. 14. pp.319: Los Angeles, CA 
Gianni L, Kearns CM, Gianni A, Capri G, Vigano L, Lacatelli A, Bonadonna G and
Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel
and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin
Oncol 13: 180–190 
Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E and Bonadonna G
(1997) Human pharmacokinetic characterization and in vitro study of the
interaction between doxorubicin and paclitaxel in women with breast cancer. 
J Clin Oncol 15: 1906–1915 
Gluck S, Germond C, Lopez P, Cano P, Doreen M, Koski T, Arnold A, Dulude H and
Gallant G (1998) A phase I trial of high-dose paclitaxel, cyclophosphamide and
mitoxantrone with autologous blood stem cell support for the treatment of
metastatic breast cancer. Eur J Cancer 34: 1008–1014 
Greinix H, Linkesh W, Seifert M, Kubista E, Czerwenka K, Elahi F, Zielinski C,
Hoecker P, Steger G, Schulenberg A, Neumeister G, Rabitsch W, Jakesz R and
Kalhs P (2000) Paclitaxel-containing high-dose chemotherapy in high-risk
breast cancer patients Acta Oncol 39: 47–52 
High-dose doxorubicin, paclitaxel, cyclophosphamide for breast cancer 1597
British Journal of Cancer (2001) 84(12), 1591–1598 © 2001 Cancer Research CampaignHenderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle J,
Cooper M, Canellos G, Borden E, Fleming G, Holland J, Graziano S,
Carpenter J, Muss H < Norton L for CALGB, ECOG, SWOG and NCCTG
(1998) Improved disease-free and overall survival from the addition of
sequential paclitaxel but not from the escalation of doxorubicin dose level in
the adjuvant chemotherapy of patients with node-positive primary breast
cancer. Proceedings of Asco Vol. 17. Pp.101a: Los Angeles, CA 
Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber M, Buzdar A,
Frye D and Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the
treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797–1805 
Hortobagyi G, Buzdar A, Theriault R, Valero V, Booser D, Frye D, Holmes F, 
Giralt S, Khouri I, Andersson B, Gajewski J, Rondon G, Smith T, Singletary
SE, Ames F, Sneige N, Strom E, McNeese M, Deisseroth A and Champlin R
(2000) Lack of efficacy of adjuvant high-dose tandem combination
chemotherapy for high-risk primary breast cancer – A randomized trial. J Natl
Cancer Inst 92: 225–233 
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations
(1958) J Am Stat Assoc 53: 457–481 
Lotz JP, Cure H, Janvier M, Morvan F, Legros M, Asselain B, Guillemot M, Roche H
and Gisselbrecht C (1999) [Intensive chemotherapy and autograft of
hematopoietic stem cells in the treatment of metastatic cancer: results of the
national protocol Pegase 04]. Intensification therapeutique et autogreffe de
cellules souches hematopoietiques (CSH) dans le traitment des cancers du sein
metastatiques: results du programme national Pegase 04. Hematol Cell Ther
41: 71–74 
Mamounas E, Brown A, Smith R, Lembersky B, Fisher B, Wickerham D, 
Wolmark N, Atkins J, Shibata H, Baez L, DeFusco P, Davila E, Thirwell M,
Bearden J, Tipping A and Scholnick A (1998) Effect of taxol duration of
infusion in advanced breast cancer: Results from NSABP B-26 trial comparing
3- to 24 hour infusion of high-dose taxol. Proceedings of Asco Vol.17. pp.
101a: Los Angeles, CA 
McCloskey DE, Kaufman SH and Prestigiacomo LJ: (1996) Paclitaxel induces
programmed cell death in MDA-MB-468 human breast cancer cells. Clin
Cancer Res 2: 847–854 
O’Shaughnessy JA, Fisherman JS and Cowan KH (1994) Combination paclitaxel
(Taxol) and doxorubicin therapy for metastatic breast cancer. Sem Oncol 21:
12–23 
Peters WP, Ross M, Vredenburg JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J,
Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B,
Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB<Budman DR and
Hurd D (1993) High-dose chemotherapy and autologous bone marrow support
as consolidation after standard-dose adjuvant therapy for high-risk primary
breast cancer. J Clin Oncol 11: 1132–1143 
Peters W, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L,
Cirrincione C, Wood W, Henderson I, Hurd D, Norton L for CALGB, SWOG
and NCIC (1999) A prospective, randomized comparison of two doses of
combination alkylating agents (AA) as consolidation after CAF in high-risk
primary breast cancer involving ten or more axillary lymph nodes (LN):
preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proceedings
of Asco Vol.18. Pp.1: Atlanta, GA 
Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes R, Lebwohl D, 
Gilewski T, Surbone A, Currie V and Hudis CA, Yao T, Klecker R, Jamis-Dow
C, Collins J, Quinlivan S, Berkery R, Taomasi F, Canetta R, Fisherman J,
Arbuck S and Norton L (1993) Paclitaxel and recombinant human granulocyte-
colony stimulating factor as initial chemotherapy for metastatic breast cancer. 
J Clin Oncol 11: 1943–1951 
Riley CA, Crom WR and Evans WE (1985) Loop-column extraction and liquid
chromatographic analysis of doxorubicin and three metabolites in plasma.
Therapeutic Drug Monitoring 7: 455–460 
Rizzo J, Riley C, Von Hoff D, Kuhn J, Phillips J and Brown T (1990) Analysis of
anticancer drugs in biological fluids: Determination of Taxol with application
to clinical pharmacokinetics. J Pharmaceut Biomed Anal 8: 
159–164 
Rodenhuis S, Richel D, van der Wall E, Schornagel J, Baars J, Koning C, Peterse J,
Borger J, Nooijen W, Bakx R and Dalesio O (1998) A randomized trial of high-
dose chemotherapy and hematopoietic progenitor cell support in operable
breast cancer with extensive axillary lymph node involvement. Lancet 352:
515–521 
Rodenhuis S, Bontenbal M, Beex L, van der Wall E, Richel D, Nooij M, Voest E,
Hupperets P, Westermann A, Dalesio O and de Vries E (2000) Randomized
phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa
and carboplatin in operable breast cancer with 4 or more axillary lymph nodes
(2000) Proceedings of Asco Vol. 19. Pp. 74a: New Orleans, LA 
Somlo G, Doroshow JH, Forman SJ, Leong L, Margolin K, Morgan R Jr, Raschko J,
Akman S, Ahn C, Nagasawa S, Harrison J, Stein A, Smith E, Sniecinski I and
Schmidt G (1994) High-dose doxorubicin, etoposide and cyclophosphamide
with stem cell reinfusion in patients with metastatic or high-risk primary breast
cancer. Cancer 73: 1678–1685 
Somlo G, Doroshow JH, Forman SJ, Odom-Maryon T, Lee J, Chow W, Hamasaki V,
Leong L, Morgan R Jr, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y,
Simpson J and Molina A (1997a) High-dose chemotherapy and stem cell
rescue in the treatment or high-risk breast cancer: Prognostic indicators of
progression-free and overall survival. J Clin Oncol 15: 2882–2893 
Somlo G, Sniecinski I, Odom-Maryon T, Nowicki B, Chow W, Hamasaki V, 
Leong L, Margolin K, Morgan Jr. R, Raschko J, Shibata S, Tetef M, Molina A,
Berenson R, Forman S and Doroshow JH (1997b) The effect of CD34 +
selection and various schedules of stem cell reinfusion and priming on
hematopoietic recovery following high-dose chemotherapy for breast cancer.
Blood 89: 1521–1528 
Sonnichsen D, Hurwitz C, Pratt C, Shuster J and Relling MV (1994) Saturable
pharmacokinetics and paclitaxel pharmacodynamics in children with solid
tumors. J Clin Oncol 12: 532–538 
Stadtmauer E, O’Neill A, Goldstein L, Criley P, Mangan K, Ingle J, Brodsky I,
Martino S, Lazarus H, Erban J, Sickles C, Glick J and the Philadelphia
Transplant Group (2000) Conventional-dose chemotherapy compared to high-
dose chemotherapy plus autologous hematopoietic stem-cell transplantation for
metastatic breast cancer N Engl J Med 342: 1069–1076 
Stemmer S, Cagnoni PJ, Shpall EJ, Bearman S, Matthes S, Dufton C, Day T, Taffs S,
Hami L, Martinez C, Purdy M, Arron J and Jones RB (1996) High-dose
paclitaxel, cyclophosphamide and cisplatin with autologous hematopoietic
support: a phase I trial. J Clin Oncol 14: 1463–1472 
Synold TW and Doroshow JH (1996) Anthracycline dose intensity: clinical
pharmacology and pharmacokinetics of high-dose doxorubicin administered as
a 96-hour continuous intravenous infusion. J Infusional Chemother 6: 69–73 
Vahdat LT, Papadopuoloski K, Balmaceda C, McGovern T, Dunleavy J, Kaufman E,
Fung B, Garrett T, Savage D, Tiersten A, Ayello J, Bagiella E, Heitjan D,
Antman K and Hesdorffer C (1998) Phase I trial of sequential high-dose
chemotherapy with escalating dose paclitaxel, melphalan and
cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor
support in women with responding metastatic breast cancer. Clin Cancer Res 4:
1689–1695 
Williams SF, Mick R, Desser R, Golick J, Beschorner J and Bitran J (1989) High-
dose consolidation therapy with autologous stem cell rescue in stage IV breast
cancer. J Clin Oncol 7: 1824–1830 
Wilson WH, Berg SL, Bryant G, Wittes R, Bates S, Fojo A, Steinberg S, Goldspiel B,
Herdt J, O’Shaughnessy J, Balis F and Chabner B (1994): Paclitaxel in
doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II
trial of 96 hour infusion. J Clin Oncol 12: 1621–1629 
Wood WC, Budman DR, Korzun AH, Cooper M, Younger J, Hart R, Moore A,
Ellerton J, Norton L, Ferree C, Ballow A, Frei E III and Henderson I (1994)
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive
breast carcinoma. N Engl J Med 330: 1253–1259 
1598 G Somlo et al 
British Journal of Cancer (2001) 84(12), 1591–1598 © 2001 Cancer Research Campaign